| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 705.4 | 736.2 | 606.5 |
| Other income | 4.1 | -0.6 | 8.2 |
| Total income | 709.5 | 735.6 | 614.8 |
| Profit before exceptional items & tax | 133.7 | 109.5 | 107.0 |
| Profit before tax | 133.7 | 109.5 | 107.0 |
| Net profit | 99.7 | 81.0 | 160.7 |
| Operating margin | 18.8% | 14.9% | 17.4% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -38.00% |
|---|---|
| Net profit, quarter on quarter | +23.10% |
| Revenue, year on year | +16.30% |
| Operating profit, year on year | -37.30% |
| Operating profit, quarter on quarter | +17.20% |
BSE results filing, NSE: EPIGRAL. Figures extracted from the filing.
Epigral Ltd: key numbers
- Share price
- ₹1,036.20
- Market cap
- ₹4,470 Cr
- Revenue (annual)
- ₹2,527 Cr
- Net profit (annual)
- ₹332.0 Cr
- P/E (TTM)
- 16.5×Sector 37.2×
- Promoter holding
- 68.83%+0.00% QoQ
- FII holding
- 1.03%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Epigral Ltd
All →Epigral Earnings Call Transcript: Key Takeaways
Epigral reported 15% revenue growth and 25% EBITDA margins despite Red Sea logistical disruptions. Management is pivoting toward high-value downstream specialty chemicals like Epoxy resins to reduce commodity exposure.
- Call
- Guides 20% growth
Epigral Capacity Expansion: ₹650 Cr Investment
Epigral Ltd will invest ₹650 Crore to add 1,25,000 TPA of Epoxy Resin & Formulations capacity at its Dahej facility, expected by H2 FY2028.
- Value
- ₹650.0 Cr
- Execution
- By H2 FY2028
Epigral Investor Presentation: Key Takeaways
Epigral reported 15% YoY revenue growth and 25% PAT growth for Q1FY27. Strategy focuses on diversifying into high-value derivatives and specialty chemicals with significant capex for Epoxy Resin and Multi-Purpose plants.
- Call
- Guides 70% growth
Epigral Results Update
Epigral reported Q1FY27 PAT of ₹99 Crore, a 25% YoY increase. The company plans ₹600 Crore capex for Epoxy Resin and Multi-Purpose Plant.
- Value
- ₹600.0 Cr
- Execution
- H2FY28
Epigral Capacity Expansion: ₹600 Cr Investment
Epigral Limited plans to establish a new manufacturing facility for Epoxy Resin and Multi-Purpose Plant at Dahej, Gujarat. The project requires an investment of ₹600 Crore.
- Value
- ₹600.0 Cr
- Execution
- By H2 FY2028
Epigral Board Meeting Date
Epigral Ltd scheduled a board meeting for July 27, 2026. The board will consider the company's first quarter unaudited financial results.